Pages that link to "Q39979475"
Jump to navigation
Jump to search
The following pages link to A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. (Q39979475):
Displaying 50 items.
- Regulation and roles of PI3Kβ, a major actor in platelet signaling and functions (Q24305005) (← links)
- Should individual PI3 kinase isoforms be targeted in cancer? (Q24309044) (← links)
- The PI3K pathway as drug target in human cancer (Q24632283) (← links)
- Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics (Q26766292) (← links)
- Inherited PTEN mutations and the prediction of phenotype (Q26772947) (← links)
- Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk (Q27315979) (← links)
- The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations (Q27851644) (← links)
- The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis (Q27851848) (← links)
- Novel Role for p110β PI 3-Kinase in Male Fertility through Regulation of Androgen Receptor Activity in Sertoli Cells (Q28546072) (← links)
- Targeting the phosphoinositide 3-kinase pathway in cancer (Q29615809) (← links)
- Targeting PI3K signalling in cancer: opportunities, challenges and limitations (Q29617685) (← links)
- PI3K and cancer: lessons, challenges and opportunities (Q30080017) (← links)
- mTOR and cancer: many loops in one pathway. (Q33348248) (← links)
- PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context (Q33674643) (← links)
- Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. (Q33726847) (← links)
- Coordinate control of host centrosome position, organelle distribution, and migratory response by Toxoplasma gondii via host mTORC2 (Q33832496) (← links)
- Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits (Q33832537) (← links)
- Activity of any class IA PI3K isoform can sustain cell proliferation and survival. (Q33952917) (← links)
- RAS Interaction with PI3K: More Than Just Another Effector Pathway (Q34202692) (← links)
- Phosphatidylinositol 3-kinase: the oncoprotein (Q34203861) (← links)
- Breast cancer genomes--form and function (Q34207688) (← links)
- Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines (Q34220097) (← links)
- Genetically engineered mouse models of PI3K signaling in breast cancer (Q34332175) (← links)
- Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment (Q34508976) (← links)
- PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma (Q34732954) (← links)
- The PI3K/Akt signal hyperactivates Eya1 via the SUMOylation pathway. (Q34766011) (← links)
- AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer (Q34990362) (← links)
- Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers (Q35051540) (← links)
- A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types (Q35215580) (← links)
- PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting (Q35260766) (← links)
- Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing (Q35926060) (← links)
- Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent (Q36062493) (← links)
- Killing of Kras-mutant colon cancer cells via Rac-independent actin remodeling by the βGBP cytokine, a physiological PI3K inhibitor therapeutically effective in vivo (Q36227159) (← links)
- p110δ PI3 kinase pathway: emerging roles in cancer (Q36647928) (← links)
- Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus (Q36841899) (← links)
- PTEN-deficient cancers depend on PIK3CB. (Q36861839) (← links)
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy (Q37031949) (← links)
- HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells (Q37044197) (← links)
- Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells (Q37131339) (← links)
- Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines (Q37215752) (← links)
- Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition (Q37331610) (← links)
- Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy (Q37367106) (← links)
- Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. (Q37656270) (← links)
- Inhibitors of phosphatidylinositol-3-kinase in cancer therapy (Q37696628) (← links)
- New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. (Q37766888) (← links)
- Potential role of PI3K inhibitors in the treatment of breast cancer. (Q37783617) (← links)
- Development of PI3K inhibitors: lessons learned from early clinical trials (Q38080710) (← links)
- Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook (Q38190918) (← links)
- ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor (Q38637153) (← links)
- CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells (Q38672092) (← links)